Aim: To investigate and compare topoisomerase II-a expression in benign prostatic hyperplasia (BPH), prostate cancer of varying Gleason scores and hormone-insensitive prostate cancer. Methods: The immunohistochemical expression of topoisomerase II-a antibody in the above-mentioned diagnostic categories was investigated and compared. Results: Increased expression of topoisomerase II-a was seen in the prostate cancers of Gleason scores 7 and 8-10 (p = 0.000) compared with prostate cancers of Gleason score 6 and BPH (p = 0.245). Statistically significant differences were found in the topoisomerase II-a gene expression between prostate cancers categorised by Gleason Score. Also, increased expression of topoisomerase II-a was seen in the known hormone-resistant prostate carcinomas compared with prostate cancers with no hormone treatment in the subgroup with Gleason scores 8-10, which approached statistical significance (p = 0.081). No statistically significant difference was observed in topoisomerase II-a expression between the groups with BPH and prostate carcinoma of Gleason score 6 (p = 0.245). Conclusion: Topoisomerase II-a expression was found to increase with the known prognostic marker Gleason score and with hormone insensitivity. Objective evidence is provided for clinical trials with drugs targeting topoisomerase II-a to be targeted to patients with prostate cancers of Gleason Score .6 and, in particular, prostate cancers of Gleason Scores 8-10.
T opoisomerase II-a is an essential cellular enzyme that functions in the segregation of newly replicated chromosome pairs, in chromosome condensation and in altering DNA superhelicity. DNA topoisomerases participate in nearly all biological processes governing DNA and untangle intertwined DNA strands before cell division by transiently breaking and then re-ligating duplex strands of DNA. Chemotherapeutic drugs that target topoisomerase II-a, such as etoposide, doxorubicin and mitoxantrone, act by stabilising a normally transient DNA-topoisomerase II complex, thus increasing the concentration of double-stranded DNA breaks. This phenomenon triggers mutagenic and cell death pathways. 1 2 Topoisomerase II-a has been reported as a prognostic marker in several tissues. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Little information is available about the expression of topoisomerase II-a in prostate carcinoma. To our knowledge, there are only two small studies 16 17 in the literature that investigate topoisomerase II-a expression in prostate cancer tissue. These studies do not investigate topoisomerase II-a expression in hormone-resistant prostate carcinoma. This is of interest as topoisomerase II-a is the target of the drug etoposide, which is an active agent in the combined chemotherapy of hormone-insensitive prostate carcinoma in clinical trials. 18 19 In this study, we examine topoisomerase II-a expression in benign prostatic hyperplasia (BPH) and prostate cancer tissue categorised by Gleason Score and by hormone sensitivity.
METHODS

Patients and tumours
Our study included 100 patients with adenocarcinoma of the prostate and 42 patients with BPH. The adenocarcinoma cases included 59 patients who had undergone transurethral resection of the prostate and 41 who had undergone radical prostatectomy. The 42 patients with BPH had undergone transurethral resection of the prostate. These patients were diagnosed with BPH between 1999 and 2003, and were identified by performing a SNOMED code search of the Adelaide and Meath Hospital Incorporating the National Children's Hospital cellular pathology database. Formalinfixed blocks from these cases were retrieved from the files. Tissue microarrays were constructed as described previously. 20 In all, samples from 138 cases were present in triplicate and included representative areas of tumour or glandular tissue from patients with BPH. Sufficient tissue from one patient with BPH was not represented on the tissue microarray and this case was excluded. In tissues from another two patients with BPH, abundant lymphocytic inflammation made it impossible to evaluate topoisomerase II-a staining of epithelial cell nuclei because of positive staining of lymphocytes by the antibodies. These cores were excluded and the remaining two cores from both of these cases were used in the evaluation.
Histopathological reports which included clinical details were reviewed for all adenocarcinoma cases. We classified cases into four categories: BPH (n = 41); well-differentiated prostate carcinoma of Gleason score 6 (n = 28); moderately differentiated prostate carcinoma of Gleason score 7 (n = 22); and poorly differentiated prostate carcinoma of Gleason scores 8-10 (n = 49). These were not selected for hormonal status. We also compared these poorly differentiated prostate carcinomas of Gleason scores 8-10 by dividing them according to hormonal status under the categories of hormone resistance after treatment (n = 15) and no hormone treatment (n = 34). The 15 cases categorised as hormone-resistant after treatment were recurrent prostate adenocarcinomas present in patients who underwent transurethral resection of the prostate in whom clinical details indicated that the patient had received antiandrogen treatment. These carcinomas had Gleason scores of 8-10. The topoisomerase II-a indices were compared between the categories using the Mann-Whitney U test.
Abbreviation: BPH, benign prostatic hyperplasia
Immunohistochemical staining
Immunohistochemical staining for topoisomerase II-a was carried out by using a monoclonal anti-topoisomerase II-a antibody at a dilution of 1:300. Sections of 5 mm thickness were studied. Antigen retrieval was performed with dewaxed sections by using a pressure cooker and the Trilogy system for 10 min. A standard avidin-biotin-peroxidase complex technique (Dako Glostrup, Denmark) was used for visualisation with diaminobenzidine as a chromogen. Sections were counterstained with haematoxylin and mounted. Tonsil samples from our routine files were used as positive controls for topoisomerase II-a.
Evaluation of immunohistochemistry
Immunohistochemical staining was evaluated by light microscopy using a 640 objective and a Miller ocular. The Miller ocular gave a square field, in the corner of which was a smaller ruled square, one ninth the area of the total square. Nuclei with strong homogeneous topoisomerase II-a staining were counted in the large square and the total number of nuclei with both positive and negative staining was counted in the small square. The number of cells in the small square was multiplied by nine to obtain the total number of cells in the large square. A mean of 240.5 epithelial cells was obtained in the prostate cancer cases and a mean of 88 epithelial cells in the cases of BPH. Five nonoverlapping square fields were counted for each tissue core, three on the y axis and two on the x axis. The percentage of positively staining nuclei within the five large squares was calculated for each core. An average result was obtained from three cores in cases with tissue microarrays in triplicate and from two cores in cases with tissue microarrays in duplicate. This served as the topoisomerase II-a index for the case. This method was used in previous studies in the evaluation of immunohistochemical results in tissue microarrays. 4 21 In addition, each topoisomerase II-a index was obtained by image analysis that used the Ariol system for tissue microarrays. An acceptable level of concordance was taken as within +10% or 210% of the topoisomerase II-a index obtained with the Miller ocular.
Of the 140 cases in total (138 in triplicate and 2 in duplicate), 14 (10%) cases showed discordance between the topoisomerase II-a indices from the Ariol image analyser and the Miller ocular. In all cases the Ariol image analyser overestimated topoisomerase II-a indices compared with the Miller ocular method.
A second observer reviewed these discordant cases. This discordant group had one case of Gleason score 7, two cases of Gleason score 8, nine of Gleason score 9 and two of Gleason score 10. These 14 cases tended to have higher topoisomerase indices (mean topoisomerase II-a index 13%) when using the Miller ocular than the average topoisomerase index for all 99 carcinoma cases analysed (mean topoisomerase II-a index 3.69%).
A review of these discordant cases by a second observer, using light microscopy and a Miller ocular, correlated within 10% of the original topoisomerase indices obtained by the first observer. The discrepancy between the results from the Ariol image analyser and light microscopy was due to difficulty in distinguishing topoisomerase-negative tumour cells from stroma by using the image analyser when there was infiltration of the stroma by a less differentiated tumour. The image analyser therefore underestimated the total number of tumour cells within a field of analysis, leading to an overestimation of the percentage of cells positive for the topoisomerase II-a antibody.
Statistics
Data were entered on to a computerised database and analysed with the SPSS statistical package and the MannWhitney U test.
Analysis of immunohistochemical results
The Mann-Whitney U test was used to determine whether there was a significant difference between the topoisomerase II-a indices in each group. Figures 1 and 2 show the results of immunohistochemical staining. Table 1 shows the median and range of topoisomerase II-a indices for each Gleason score. Tables 2 and 3 show median and range for the categories statistically analysed.
RESULTS
Immunohistochemical staining
Statistical analysis
We found no significant difference between the groups with BPH and with prostate carcinoma of Gleason score 6 (p = 0.245). The difference between the groups with prostate carcinoma of Gleason scores 6 and 7 was significant (p,0.008). In addition, the groups with prostate carcinoma of Gleason score 7 and Gleason scores 8-10 (not selected for hormonal status) differed significantly (p = 0).
When the category of cases with Gleason Scores 8-10 was analysed with regard to hormone treatment and insensitivity (n = 15) and cases with no hormone treatment (n = 34), the difference in topoisomerase indices approached significance (p = 0.081). Table 4 shows the results of analysis by the Mann-Whitney U test. Figures 3 and 4 show scatter plots generated from the data.
DISCUSSION
Little information is available on the expression of topoisomerase II-a in prostate carcinoma tissue or, in particular, in identifying whether its expression is increased in comparison with BPH. To our knowledge, only two papers in the literature investigated topoisomerase II-a expression in prostate carcinoma tissue 16 17 and one paper attempted to compare topoisomerase II-a expression in prostate cancer and BPH. 17 That study, which investigated only 10 cases, reported little expression of topoisomerase II-a in BPH. In contrast with this study, we identified topoisomerase II-a expression in BPH (range 0-3.3). In addition, our study showed no statistically significant difference in topoisomerase II-a expression between prostate carcinoma of Gleason Score 6 and BPH.
The previous two studies conclude that topoisomerase II-a expression correlates with Gleason score, which is supported also by our larger study. We also identified a statistically significant difference in topoisomerase II-a expression between prostate cancers classified with respect to Gleason score.
To our knowledge, our study is the first of its kind that examined topoisomerase II-a expression in hormoneresistant prostate carcinoma. This is of particular interest as topoisomerase II-a is the target of the drug etoposide, which is an active agent in the combined chemotherapy of hormone-insensitive prostate carcinoma in clinical trials. We identified increased topoisomerase II-a expression in the hormone-resistant prostate carcinomas compared with prostate carcinomas with no hormone treatment, which approached statistical significance. The number of cases of hormoneresistant prostate cancer of Gleason scores 8-10 was limited (n = 15) compared with that of prostate carcinoma of Gleason scores 8-10 with no hormone treatment (n = 34). Further studies with increased statistical power and increased numbers of hormone-resistant prostate carcinoma are required to show conclusively that this hormone-resistant subgroup of prostate carcinoma shows increased topoisomerase II-a expression compared with prostate carcinoma with no hormone treatment. The importance of this finding would be in providing clinicopathological correlation for the fact that this clinical subgroup of hormone-resistant prostate carcinomas has shown the best response to the drug etoposide that targets the topoisomerase II-a gene. 18 19 Our study showed with statistical significance that higher topoisomerase II-a immunoexpression was associated with poorly differentiated prostate carcinomas (Gleason scores 8-10) compared with moderately differentiated prostate carcinoma (Gleason score 7) , and between moderately differentiated prostate carcinoma (Gleason score 7) and welldifferentiated prostate carcinoma (Gleason score 6). Several studies have correlated the level of topoisomerase II-a expression with a response to anti-topoisomerase II-a drugs in cancer cell lines. [22] [23] [24] As treatment options for advanced prostate carcinoma are limited, and advanced prostate carcinomas are more likely to be of higher Gleason score, it is important to attempt to identify potential targets for chemotherapy agents in this patient group.
In conclusion, we believe that the topoisomerase II-a gene is a potential target for chemotherapy in this group of patients, particularly in patients with prostate carcinomas of Gleason scores 8-10. 
